Literature DB >> 11839405

Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines.

L Kapusta1, J M Thijssen, J Groot-Loonen, J A van Druten, O Daniëls.   

Abstract

This study investigated improvement of diagnosing myocardial damage caused by anthracyclines using tissue Doppler imaging (TDI). The optimal set of conventional echocardiographic and/or TDI parameters, needed for the discrimination of survivors from healthy controls, was retrospectively assessed. A total of 60 patients and 99 controls, age range 8.5 to 17.6 years, were studied. The survivors received 50 to 400 mg/m(2) cumulative dose of anthracyclines, with a mean follow-up of 7.3 (+/-2.3) years. The parameters used in the discriminant score (S-score) were selected from a large set of 51 echocardiographic parameters, using logistic regression analysis (stepwise selection). The correct classification probability (C-index) and the generalized distance (d) between the distributions of S-scores were used to measure the overall discriminative performance of each echocardiographic technique separately and in combination. The overall discriminative performance of the conventional echo-Doppler parameters (C = 77.3%, d = 1.04) was lower than that of the TDI (C = 84.2%, d = 1.37); the highest C-index was obtained using both techniques (C = 89.2%, d = 1.66). The set of parameters includes: LV fractional shortening and MV early diastolic flow velocity, two long-axis and five apical 4-CV TDI wall velocities (systolic and diastolic). In the patient group, the S-score was positively associated with cumulative dose of anthracyclines (p = 0.05) and duration of treatment (p = 0.01). The diagnostic index S-score, based on a limited number of variables from both techniques simultaneously, could retrospectively discriminate asymptomatic children with anthracycline-induced cardiomyopathy from healthy controls. The potentials of the S-score for serial and prospective studies are further investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11839405     DOI: 10.1016/s0301-5629(01)00470-7

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  6 in total

1.  Myocardial peak systolic velocity-a tool for cardiac screening of HIV-exposed uninfected children.

Authors:  Paula Martins; António Pires; M Emanuel Albuquerque; Manuel Oliveira-Santos; José Santos; Cristina Sena; Raquel Seiça
Journal:  Eur J Pediatr       Date:  2019-11-25       Impact factor: 3.183

2.  Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer.

Authors:  Andrew C Dietz; Shanthi Sivanandam; Suma Konety; Christopher L Kaufman; Ryan M Gage; Aaron S Kelly; Joseph P Neglia; Daniel A Mulrooney
Journal:  J Cancer Surviv       Date:  2013-12-07       Impact factor: 4.442

3.  Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.

Authors:  András Csaba Nagy; Zsuzsanna Cserép; Edina Tolnay; Tamás Nagykálnai; Tamás Forster
Journal:  Pathol Oncol Res       Date:  2008-03-15       Impact factor: 3.201

4.  Tissue Doppler Imaging and Focal, Late-Onset Anthracycline-Induced Cardiovascular Disease in Long Term Survivors of Childhood Cancer: A Research Article.

Authors:  Prakadeshwari Rajapreyar; Adonis Lorenzana; Anuradha Prabhu; Susan Szpunar; Premchand Anne
Journal:  J Clin Diagn Res       Date:  2016-08-01

5.  Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

Authors:  Ruxandra Jurcut; Hans Wildiers; Javier Ganame; Jan D'hooge; Robert Paridaens; Jens-Uwe Voigt
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

6.  Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer.

Authors:  R Altena; E C de Haas; J Nuver; C A J Brouwer; M P van den Berg; A J Smit; A Postma; D Th Sleijfer; J A Gietema
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.